Cover Image
市場調查報告書

手術後疼痛:開發中產品分析

Post-Operative Pain - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 227536
出版日期 內容資訊 英文 187 Pages
訂單完成後即時交付
價格
Back to Top
手術後疼痛:開發中產品分析 Post-Operative Pain - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 187 Pages
簡介

疼痛是讓術後患者感到壓力的負面情況之一。危險因子有年齡及恐懼·不安的程度、外科手術過程、個人選擇、和對藥物的反應等。主要的治療藥有止痛藥和麻醉劑等。

本報告提供全球各國治療全球各國的手術後疼痛所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

手術後疼痛概要

治療藥的開發

  • 手術後疼痛開發中產品:概要
  • 手術後疼痛開發中產品:比較分析

各企業開發中的手術後疼痛治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

手術後疼痛治療藥:開發中的產品一覽(各企業)

手術後疼痛開發治療藥的企業

  • AcelRx Pharmaceuticals, Inc.
  • Adynxx, Inc.
  • AngioChem Inc.
  • AskAt Inc.
  • Boehringer Ingelheim GmbH
  • Cara Therapeutics, Inc.
  • Colby Pharmaceutical Company
  • Cytogel Pharma, LLC
  • Dompe Farmaceutici S.p.A.
  • DURECT Corporation
  • Echo Pharmaceuticals B.V.
  • 爬蔓植物製藥
  • Galleon Pharmaceuticals
  • Grunenthal GmbH
  • GW Pharmaceuticals Plc
  • Heron Therapeutics, Inc.
  • Immupharma Plc
  • Innocoll AG
  • INSYS Therapeutics, Inc.
  • Laboratorios Del Dr. Esteve S.A.
  • Lipocure Ltd.
  • Liquidia Technologies, Inc.
  • Medtronic plc
  • Orbis Biosciences, Inc.
  • Orion Oyj
  • Pacira Pharmaceuticals, Inc.
  • PainReform Ltd.
  • Pharmazz, Inc.
  • PhytoHealth Corporation
  • Proteus SA
  • Recro Pharma, Inc.
  • Relmada Therapeutics, Inc.
  • Serina Therapeutics, Inc.
  • SteadyMed Therapeutics, Inc.
  • 武田藥品工業
  • The Medicines Company
  • Trevena, Inc.

手術後疼痛:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

手術後疼痛治療藥:暫停開發的產品

手術後疼痛治療藥:中止開發的產品

手術後疼痛相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8219IDB

Summary

Global Markets Direct's, 'Post-Operative Pain - Pipeline Review, H2 2016', provides an overview of the Post-Operative Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Post-Operative Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Post-Operative Pain
  • The report reviews pipeline therapeutics for Post-Operative Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Post-Operative Pain therapeutics and enlists all their major and minor projects
  • The report assesses Post-Operative Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Post-Operative Pain

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Post-Operative Pain
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Post-Operative Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Post-Operative Pain Overview
  • Therapeutics Development
    • Pipeline Products for Post-Operative Pain - Overview
  • Post-Operative Pain - Therapeutics under Development by Companies
  • Post-Operative Pain - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Post-Operative Pain - Products under Development by Companies
  • Post-Operative Pain - Companies Involved in Therapeutics Development
    • AcelRx Pharmaceuticals, Inc.
    • Adynxx, Inc.
    • AngioChem Inc.
    • AskAt Inc.
    • Boehringer Ingelheim GmbH
    • Cara Therapeutics, Inc.
    • Colby Pharmaceutical Company
    • Cytogel Pharma, LLC
    • Dompe Farmaceutici S.p.A.
    • DURECT Corporation
    • Echo Pharmaceuticals B.V.
    • Fujimoto Pharmaceutical Corporation
    • Galleon Pharmaceuticals
    • Grunenthal GmbH
    • GW Pharmaceuticals Plc
    • Heron Therapeutics, Inc.
    • Immupharma Plc
    • Innocoll AG
    • INSYS Therapeutics, Inc.
    • Laboratorios Del Dr. Esteve S.A.
    • Lipocure Ltd.
    • Liquidia Technologies, Inc.
    • Medtronic plc
    • Orbis Biosciences, Inc.
    • Orion Oyj
    • Pacira Pharmaceuticals, Inc.
    • PainReform Ltd.
    • Pharmazz, Inc.
    • PhytoHealth Corporation
    • Proteus SA
    • Recro Pharma, Inc.
    • Relmada Therapeutics, Inc.
    • Serina Therapeutics, Inc.
    • SteadyMed Therapeutics, Inc.
    • Takeda Pharmaceutical Company Limited
    • The Medicines Company
    • Trevena, Inc.
  • Post-Operative Pain - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (bupivacaine hydrochloride + meloxicam) - Drug Profile
    • AM-4 - Drug Profile
    • ANG-2002 - Drug Profile
    • ARX-04 - Drug Profile
    • AYX-1 - Drug Profile
    • BI-1026706 - Drug Profile
    • bupivacaine hydrochloride - Drug Profile
    • bupivacaine hydrochloride - Drug Profile
    • bupivacaine hydrochloride - Drug Profile
    • bupivacaine hydrochloride - Drug Profile
    • bupivacaine hydrochloride ER - Drug Profile
    • bupivacaine hydrochloride SR - Drug Profile
    • buprenorphine hydrochloride - Drug Profile
    • CPC-123 - Drug Profile
    • CR-4056 - Drug Profile
    • Cyt-1010 - Drug Profile
    • dexmedetomidine hydrochloride - Drug Profile
    • DF-2755A - Drug Profile
    • difelikefalin - Drug Profile
    • difluprednate XR - Drug Profile
    • dronabinol - Drug Profile
    • Drug for Post Operative Pain - Drug Profile
    • ECP-1014 - Drug Profile
    • fadolmidine hydrochloride - Drug Profile
    • fentanyl - Drug Profile
    • GAL-044 - Drug Profile
    • grapiprant - Drug Profile
    • IPP-102199 - Drug Profile
    • ketamine hydrochloride - Drug Profile
    • ketorolac tromethamine - Drug Profile
    • levorphanol tartrate ER - Drug Profile
    • MDT-10013 - Drug Profile
    • meloxicam - Drug Profile
    • meloxicam ER - Drug Profile
    • meloxicam ER - Drug Profile
    • MR-309 - Drug Profile
    • nabiximols - Drug Profile
    • nalbuphine hydrochloride - Drug Profile
    • neosaxitoxin - Drug Profile
    • oliceridine - Drug Profile
    • PMZ-2010 - Drug Profile
    • RBM-004 - Drug Profile
    • ropivacaine - Drug Profile
    • ropivacaine ER - Drug Profile
    • SER-226 - Drug Profile
    • Small Molecule for Post-Operative Pain - Drug Profile
    • sufentanil citrate - Drug Profile
    • tapentadol hydrochloride - Drug Profile
    • tramadol hydrochloride - Drug Profile
    • tramadol hydrochloride ER - Drug Profile
    • URB-937 - Drug Profile
    • VVZ-149 - Drug Profile
  • Post-Operative Pain - Dormant Projects
  • Post-Operative Pain - Discontinued Products
  • Post-Operative Pain - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Post-Operative Pain, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals, Inc., H2 2016
  • Post-Operative Pain - Pipeline by Adynxx, Inc., H2 2016
  • Post-Operative Pain - Pipeline by AngioChem Inc., H2 2016
  • Post-Operative Pain - Pipeline by AskAt Inc., H2 2016
  • Post-Operative Pain - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Post-Operative Pain - Pipeline by Cara Therapeutics, Inc., H2 2016
  • Post-Operative Pain - Pipeline by Colby Pharmaceutical Company, H2 2016
  • Post-Operative Pain - Pipeline by Cytogel Pharma, LLC, H2 2016
  • Post-Operative Pain - Pipeline by Dompe Farmaceutici S.p.A., H2 2016
  • Post-Operative Pain - Pipeline by DURECT Corporation, H2 2016
  • Post-Operative Pain - Pipeline by Echo Pharmaceuticals B.V., H2 2016
  • Post-Operative Pain - Pipeline by Fujimoto Pharmaceutical Corporation, H2 2016
  • Post-Operative Pain - Pipeline by Galleon Pharmaceuticals, H2 2016
  • Post-Operative Pain - Pipeline by Grunenthal GmbH, H2 2016
  • Post-Operative Pain - Pipeline by GW Pharmaceuticals Plc, H2 2016
  • Post-Operative Pain - Pipeline by Heron Therapeutics, Inc., H2 2016
  • Post-Operative Pain - Pipeline by Immupharma Plc, H2 2016
  • Post-Operative Pain - Pipeline by Innocoll AG, H2 2016
  • Post-Operative Pain - Pipeline by INSYS Therapeutics, Inc., H2 2016
  • Post-Operative Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016
  • Post-Operative Pain - Pipeline by Lipocure Ltd., H2 2016
  • Post-Operative Pain - Pipeline by Liquidia Technologies, Inc., H2 2016
  • Post-Operative Pain - Pipeline by Medtronic plc, H2 2016
  • Post-Operative Pain - Pipeline by Orbis Biosciences, Inc., H2 2016
  • Post-Operative Pain - Pipeline by Orion Oyj, H2 2016
  • Post-Operative Pain - Pipeline by Pacira Pharmaceuticals, Inc., H2 2016
  • Post-Operative Pain - Pipeline by PainReform Ltd., H2 2016
  • Post-Operative Pain - Pipeline by Pharmazz, Inc., H2 2016
  • Post-Operative Pain - Pipeline by PhytoHealth Corporation, H2 2016
  • Post-Operative Pain - Pipeline by Proteus SA, H2 2016
  • Post-Operative Pain - Pipeline by Recro Pharma, Inc., H2 2016
  • Post-Operative Pain - Pipeline by Relmada Therapeutics, Inc., H2 2016
  • Post-Operative Pain - Pipeline by Serina Therapeutics, Inc., H2 2016
  • Post-Operative Pain - Pipeline by SteadyMed Therapeutics, Inc., H2 2016
  • Post-Operative Pain - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Post-Operative Pain - Pipeline by The Medicines Company, H2 2016
  • Post-Operative Pain - Pipeline by Trevena, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Post-Operative Pain - Dormant Projects, H2 2016
  • Post-Operative Pain - Dormant Projects (Contd..1), H2 2016
  • Post-Operative Pain - Dormant Projects (Contd..2), H2 2016
  • Post-Operative Pain - Dormant Projects (Contd..3), H2 2016
  • Post-Operative Pain - Dormant Projects (Contd..4), H2 2016
  • Post-Operative Pain - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Post-Operative Pain, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top